Lanreotid SUN: Uses, Dosage & Side Effects

What Is Lanreotid SUN and What Is It Used For?

Lanreotid SUN contains the active substance lanreotide, a synthetic octapeptide analogue of the naturally occurring hormone somatostatin. Somatostatin is a peptide hormone produced in the hypothalamus, gastrointestinal tract, and pancreas that plays a critical regulatory role in inhibiting the secretion of numerous hormones throughout the body. However, natural somatostatin has an extremely short half-life of approximately 1–3 minutes in the circulation, making it impractical for therapeutic use. Lanreotide was developed as a long-acting analogue that retains the key biological activities of somatostatin while providing a dramatically extended duration of action, enabling once-monthly dosing.

The mechanism of action of lanreotide centers on its preferential binding to somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), which are the receptor subtypes most commonly expressed in the pituitary gland and in neuroendocrine tumors. By activating these receptors, lanreotide triggers intracellular signaling cascades that result in the inhibition of hormone secretion, reduction of cell proliferation, and induction of apoptosis (programmed cell death) in susceptible tumor cells. In the pituitary gland, activation of SSTR2 directly suppresses the release of growth hormone (GH) from somatotroph adenomas, leading to reduced circulating levels of both GH and its downstream mediator, insulin-like growth factor 1 (IGF-1). In neuroendocrine tumors, lanreotide suppresses the release of serotonin, chromogranin A, and other bioactive peptides responsible for the clinical symptoms of carcinoid syndrome.

Lanreotid SUN is indicated for the treatment of three principal clinical conditions. The first is acromegaly, a chronic hormonal disorder caused by excessive production of growth hormone, usually from a pituitary adenoma. Acromegaly leads to progressive enlargement of the hands, feet, and facial features, as well as serious systemic complications including cardiovascular disease, diabetes mellitus, joint disorders, and sleep apnea. Lanreotide is used when surgery has not achieved adequate biochemical control (normalization of GH and IGF-1 levels), when surgery is not feasible or has been refused by the patient, or as a bridging therapy while awaiting the effects of radiotherapy. Clinical studies have shown that lanreotide normalizes GH levels in approximately 50–70% and IGF-1 levels in 40–60% of patients with acromegaly, depending on the baseline hormone levels and the dose used.

The second indication is the symptomatic management of neuroendocrine tumors, particularly the control of diarrhea and flushing episodes associated with carcinoid syndrome. Carcinoid tumors, which arise most commonly from the midgut, secrete serotonin and other vasoactive substances into the systemic circulation, producing the characteristic symptoms of carcinoid syndrome: episodic flushing (reddening of the face and upper body), profuse watery diarrhea, bronchospasm, and in some cases, carcinoid heart disease. Lanreotide effectively reduces both the frequency and severity of these symptoms by inhibiting the secretion of serotonin and other tumor-derived peptides.

The third and increasingly important indication is the antiproliferative treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The landmark CLARINET trial (Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumours), published in the New England Journal of Medicine in 2014, demonstrated that lanreotide 120 mg administered every 28 days significantly prolonged progression-free survival (PFS) compared with placebo in patients with well-differentiated, metastatic GEP-NETs. At the end of the study period, the median PFS had not been reached in the lanreotide group versus 18 months in the placebo group, with a hazard ratio of 0.47 (95% CI, 0.30–0.73; p < 0.001). This study established lanreotide as a first-line treatment option for tumor growth control in GEP-NETs, regardless of whether the tumors were functional (producing hormonal symptoms) or non-functional.

What Should You Know Before Taking Lanreotid SUN?

Contraindications

Lanreotid SUN is contraindicated in patients with known hypersensitivity to lanreotide, to somatostatin, or to any of the excipients in the formulation. Although severe allergic reactions to lanreotide are rare, anaphylactic reactions have been reported in post-marketing surveillance. If you have previously experienced an allergic reaction to octreotide (another somatostatin analogue) or to any peptide-based medication, discuss this with your doctor before starting lanreotide, as cross-reactivity between somatostatin analogues is theoretically possible.

There are no absolute contraindications related to specific organ dysfunction, but several conditions require careful clinical assessment and monitoring before and during treatment. Your doctor will evaluate the risk-benefit ratio based on your individual medical history and the severity of the condition being treated.

Warnings and Precautions

Before starting Lanreotid SUN, discuss the following with your healthcare provider:

• Gallbladder disease: Somatostatin analogues, including lanreotide, reduce gallbladder contractility and decrease bile secretion, which can lead to gallbladder sludge and gallstone formation. The incidence of cholelithiasis with long-term lanreotide use is reported at 15–30% in clinical studies. Patients should undergo baseline and periodic gallbladder ultrasound. Most gallstones associated with somatostatin analogues are asymptomatic and do not require intervention, but symptomatic gallstones or complications such as cholecystitis may require surgical management.
• Diabetes mellitus: Lanreotide affects glucose metabolism by inhibiting the secretion of both insulin and glucagon. This dual effect can result in either hyperglycemia or hypoglycemia, depending on the patient's baseline glucose tolerance, existing diabetes medications, and the specific clinical context. Patients with diabetes mellitus or impaired glucose tolerance should monitor blood glucose levels more frequently when starting lanreotide or changing the dose. Adjustments to insulin or oral antidiabetic medications may be necessary.
• Cardiac disorders: Bradycardia (slowing of the heart rate) has been reported with somatostatin analogues. Patients with pre-existing cardiac conduction disorders, those taking beta-blockers or calcium channel blockers, or patients with conditions predisposing to bradycardia should be monitored. Lanreotide should be used with caution in patients with a history of clinically significant bradyarrhythmias.
• Thyroid function: Long-term treatment with somatostatin analogues may suppress thyroid-stimulating hormone (TSH) secretion, potentially leading to hypothyroidism. Thyroid function should be monitored periodically during treatment, particularly in patients who develop symptoms suggestive of hypothyroidism such as fatigue, weight gain, cold intolerance, or depression.

Pregnancy and Breastfeeding

There are limited data on the use of lanreotide in pregnant women. Animal studies have not revealed direct harmful effects on embryonic or fetal development at clinically relevant doses. However, as a precaution, Lanreotid SUN should not be used during pregnancy unless the clinical condition of the mother requires treatment and the potential benefits clearly outweigh the potential risks to the fetus. Women of childbearing potential should use effective contraception during treatment with lanreotide.

It is not known whether lanreotide is excreted in human breast milk. Given its peptide nature, oral absorption by the nursing infant is unlikely to be clinically significant. However, a risk to the breastfed infant cannot be excluded. The decision to breastfeed during lanreotide treatment should be made in consultation with your doctor, considering both the benefit of breastfeeding for the child and the benefit of treatment for the mother.

Children and Adolescents

The safety and efficacy of Lanreotid SUN have not been established in children and adolescents under 18 years of age. Acromegaly and neuroendocrine tumors are uncommon in the pediatric population, and there are insufficient clinical data to recommend lanreotide use in this age group. If treatment with a somatostatin analogue is considered necessary in a pediatric patient, this should be managed by a specialist center with experience in treating these conditions in children.

Driving and Operating Machinery

Lanreotide has no or negligible influence on the ability to drive and use machines. However, dizziness and asthenia (weakness) have been reported as uncommon side effects. If you experience these symptoms, exercise caution when driving or operating machinery until the symptoms resolve.

How Does Lanreotid SUN Interact with Other Drugs?

Because lanreotide is a peptide that is degraded by peptidases rather than metabolized by hepatic cytochrome P450 (CYP450) enzymes, it has a low potential for traditional pharmacokinetic drug interactions. However, its pharmacodynamic effects on hormone secretion, gallbladder motility, gastrointestinal absorption, and cardiac electrophysiology can result in clinically significant interactions with several drug classes. Understanding these interactions is essential for safe prescribing, particularly in patients with acromegaly and neuroendocrine tumors who often receive complex multi-drug regimens.

The following table summarizes the most important known and potential drug interactions with lanreotide:

Important Pharmacodynamic Interactions

The most clinically significant interaction involves antidiabetic medications. Lanreotide inhibits the secretion of both insulin and glucagon from the pancreas. The net effect on blood glucose depends on the balance between these two opposing hormonal changes. In most patients, the predominant effect is mild hyperglycemia due to insulin suppression, but some patients (particularly those on insulin therapy) may experience hypoglycemia. The Endocrine Society recommends that glucose monitoring be intensified during the first 2–3 months of lanreotide therapy and whenever the dose is changed. Patients with well-controlled type 2 diabetes on metformin alone may not require significant dose adjustments, while patients on insulin or sulfonylureas should be monitored more closely.

The interaction with cardiac medications deserves particular attention in patients with acromegaly, who have an elevated prevalence of cardiovascular disease. Lanreotide can cause bradycardia by reducing sympathetic nervous system activity and through direct effects on cardiac conduction. When combined with beta-blockers (particularly non-selective agents such as propranolol or sotalol), non-dihydropyridine calcium channel blockers (verapamil, diltiazem), or other drugs that slow heart rate (ivabradine, digoxin), the risk of clinically significant bradycardia is increased. Baseline ECG and regular heart rate monitoring are recommended in these patients.

Lanreotide reduces gastrointestinal motility and may slow gastric emptying. This can affect the rate and extent of absorption of orally administered drugs. In particular, the absorption of ciclosporin (cyclosporine) has been shown to be reduced when co-administered with somatostatin analogues. Patients receiving ciclosporin for immunosuppression (e.g., post-transplant) should have their ciclosporin trough levels monitored more frequently during initiation and dose changes of lanreotide.

What Is the Correct Dosage of Lanreotid SUN?

The dosage of Lanreotid SUN varies according to the indication being treated and the individual patient's clinical response. The medication is available as a solution for injection in pre-filled syringes containing 60 mg, 90 mg, or 120 mg of lanreotide (as the acetate salt). The injection is administered as a deep subcutaneous injection into the upper outer quadrant of the buttock. The Autogel formulation creates a semi-solid depot at the injection site that provides sustained drug release over the 28-day dosing interval, achieving stable therapeutic plasma concentrations without the peaks and troughs associated with shorter-acting formulations.

Adults

Acromegaly: The goal of treatment in acromegaly is biochemical control, defined as normalization of GH levels (typically < 2.5 ng/mL or < 1.0 ng/mL during an oral glucose tolerance test) and age- and sex-adjusted IGF-1 levels within the normal reference range. Treatment usually begins with lanreotide 60 mg or 90 mg every 28 days. After three months of treatment, GH and IGF-1 levels are reassessed, and the dose is adjusted accordingly. If GH and IGF-1 levels remain elevated, the dose can be increased to 120 mg. If biochemical control is achieved at 90 mg, some patients may be maintained on 60 mg. In patients with excellent biochemical control over an extended period, the dosing interval may be extended to every 6–8 weeks, although this off-label approach requires careful monitoring.

Neuroendocrine tumors (symptom control): For management of symptoms related to functional neuroendocrine tumors, the starting dose is typically 60–120 mg every 28 days, with the dose adjusted based on the degree of symptom relief. Many patients with carcinoid syndrome require 120 mg to achieve adequate control of flushing and diarrhea episodes. In patients with refractory symptoms, shorter dosing intervals (every 21 days) or the addition of short-acting octreotide for breakthrough symptoms may be considered.

GEP-NET antiproliferative treatment: Based on the CLARINET trial protocol, the recommended dose for tumor growth control in well-differentiated (Grade 1 or Grade 2, Ki-67 ≤ 10%), metastatic or locally advanced, unresectable GEP-NETs is lanreotide 120 mg administered by deep subcutaneous injection every 28 days. Treatment should continue for as long as clinical benefit is observed and no disease progression occurs. If disease progression is confirmed radiologically, treatment options should be reconsidered in a multidisciplinary team setting.

Elderly Patients

No dose adjustment is required for elderly patients based on age alone. Clinical experience with lanreotide in patients aged 65 years and older is extensive, and no clinically meaningful differences in safety or efficacy have been observed compared with younger adults. However, elderly patients are more likely to have renal or hepatic impairment, cardiac conduction disorders, and other comorbidities that may require closer monitoring. The general recommendation is to start at the lower end of the dose range and titrate cautiously, with regular assessment of renal function, hepatic function, thyroid function, and cardiac rhythm.

Renal and Hepatic Impairment

No dose adjustment is necessary for patients with mild to moderate renal or hepatic impairment. The pharmacokinetics of lanreotide have not been specifically studied in patients with severe renal failure (creatinine clearance < 15 mL/min) or severe hepatic insufficiency (Child-Pugh C). In these populations, lanreotide should be used with caution, and dose adjustments based on clinical response and tolerability may be needed. Lanreotide is primarily degraded by peptide hydrolysis and is excreted via the biliary system, with renal excretion playing a minor role.

Missed Dose

If a dose of Lanreotid SUN is missed, it should be administered as soon as possible. Given the 28-day dosing interval and the depot formulation's sustained release characteristics, therapeutic drug levels are maintained for some time after the intended injection date. However, delays of more than a few days may result in suboptimal hormone suppression. After a missed dose, the next injection should be given at the originally scheduled interval from the make-up dose (i.e., 28 days from the delayed injection), not from the originally planned date. Do not administer a double dose to make up for a missed injection.

Overdose

Limited information is available on overdose with lanreotide. In the event of accidental overdose, management should be symptomatic and supportive. Based on the pharmacological profile of somatostatin analogues, overdose symptoms may include gastrointestinal disturbances (nausea, vomiting, abdominal cramps, diarrhea), flushing, dizziness, hypoglycemia or hyperglycemia, and bradycardia. There is no specific antidote for lanreotide. Given its depot formulation and prolonged duration of action, patients who have received an overdose should be monitored for an appropriate period (potentially several weeks) depending on the symptoms observed.

What Are the Side Effects of Lanreotid SUN?

Like all medicines, Lanreotid SUN can cause side effects, although not everybody gets them. The side effect profile of lanreotide is well-characterized from clinical trials involving thousands of patients and from extensive post-marketing surveillance over more than two decades. Most side effects are mild to moderate in severity and are related to the pharmacological activity of somatostatin analogues on the gastrointestinal tract, gallbladder, and endocrine system.

The gastrointestinal side effects are primarily a consequence of lanreotide's inhibitory effects on gastrointestinal motility, gastric acid secretion, pancreatic enzyme secretion, and bile flow. These effects are most pronounced during the initial months of treatment and frequently diminish in intensity as the body adapts to the medication. Patients should be informed that gastrointestinal symptoms, while uncomfortable, are expected and typically manageable. The gallbladder effects, however, may be persistent and cumulative over time, necessitating ongoing surveillance.

The following side effect frequency grid summarizes the adverse reactions reported with lanreotide, organized by frequency category according to international conventions:

Managing Gastrointestinal Side Effects

Gastrointestinal side effects are the most frequently reported adverse reactions with lanreotide and are directly related to its suppression of gastrointestinal secretions and motility. Diarrhea is the single most common side effect, affecting up to 65% of patients during the initial weeks of treatment, although the severity typically decreases significantly after the first 2–4 injections. Dietary modifications can help manage diarrhea, including eating smaller, more frequent meals, reducing fat intake (as pancreatic lipase secretion is reduced by somatostatin analogues), and maintaining adequate hydration. In some cases, loperamide or other antidiarrheal agents may be used for symptomatic relief.

Abdominal pain and cramping are common during the first few months and usually resolve with continued treatment. Steatorrhea (fatty stools) can occur due to reduced pancreatic enzyme secretion and may lead to malabsorption of fat-soluble vitamins (A, D, E, K) in some patients. If steatorrhea is persistent, pancreatic enzyme supplementation may be considered. Nausea is generally mild and tends to improve with time; taking meals at regular intervals and avoiding large fatty meals can help.

Gallbladder Monitoring

Gallstone formation is a predictable pharmacological consequence of somatostatin analogue therapy. Lanreotide reduces gallbladder contractility by approximately 50% and decreases bile salt secretion, creating conditions favorable for cholesterol crystal precipitation and stone formation. The cumulative incidence of gallstones increases with the duration of treatment, reaching 20–30% after 3–5 years of continuous therapy. Regular ultrasound monitoring (every 6–12 months) allows early detection. Most treatment-related gallstones are cholesterol stones that remain asymptomatic. Prophylactic cholecystectomy is not recommended; management should be guided by the development of symptoms or complications.

How Should You Store Lanreotid SUN?

Proper storage of Lanreotid SUN is essential to maintain the stability and efficacy of the lanreotide formulation. The Autogel formulation is a supersaturated solution that forms a semi-solid gel depot after injection, and temperature extremes or improper handling can compromise this process and affect drug delivery.

Lanreotid SUN pre-filled syringes should be stored in a refrigerator at 2–8°C (36–46°F). The syringes should be kept in the original outer carton to protect the product from light. Do not freeze the product, as freezing may irreversibly damage the formulation and alter the drug release profile. If the product has been accidentally frozen, it should not be used.

Before administration, the pre-filled syringe should be removed from the refrigerator and allowed to reach room temperature for approximately 30 minutes. Injecting a cold solution can be more painful and may affect the formation of the subcutaneous depot. The syringe should not be heated by any artificial means (e.g., microwave, hot water); simply leaving it at room temperature is sufficient.

Keep Lanreotid SUN out of the sight and reach of children. Do not use this medicine after the expiry date stated on the carton and syringe label (EXP). The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste; return unused medicines to your pharmacy for safe disposal.

What Does Lanreotid SUN Contain?

The active substance in Lanreotid SUN is lanreotide, present as lanreotide acetate. Lanreotide is a synthetic cyclic octapeptide (8-amino acid peptide) with the amino acid sequence D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, where a disulfide bridge between the two cysteine residues creates the cyclic structure essential for biological activity. This molecular structure closely mimics the active binding region of natural somatostatin while providing substantially greater resistance to enzymatic degradation, resulting in a half-life of approximately 23–30 days compared with somatostatin's 1–3 minute half-life.

Lanreotid SUN is available in three strengths, each in a single pre-filled syringe:

• 60 mg: Each pre-filled syringe contains 60 mg of lanreotide (as acetate)
• 90 mg: Each pre-filled syringe contains 90 mg of lanreotide (as acetate)
• 120 mg: Each pre-filled syringe contains 120 mg of lanreotide (as acetate)

The other ingredients (excipients) in Lanreotid SUN include water for injections and acetic acid (glacial) for pH adjustment. The Autogel formulation is notable for its simplicity, containing no polymer matrix, surfactants, or other excipients commonly found in long-acting injectable formulations. Instead, the sustained-release properties are inherent to the physical-chemical characteristics of lanreotide itself: at the concentration used in the Autogel formulation, lanreotide molecules self-assemble into organized nanotubes that form a semi-solid gel immediately upon subcutaneous injection. This gel depot then slowly dissolves over the course of 28 days, releasing lanreotide at a controlled rate into the systemic circulation.

The product appears as a white to slightly yellow supersaturated solution in a pre-filled syringe with an automatic needle safety system. The syringe is equipped with a needle guard to prevent needlestick injuries after use. The entire administration system is designed for single use only and should not be resterilized or reused.